Investment Rating - The report maintains a "Buy" rating for Baidu Group-SW (09888.HK) [1] Core Views - Baidu's AI infrastructure capabilities are leading, and the company is expected to see significant commercialization opportunities in its AI business [1][8] - The company's AI cloud business is experiencing rapid growth, driven by strong demand for AI solutions and the advantages of its full-stack AI capabilities [7][8] - Baidu's AI native marketing services are increasingly penetrating traditional advertising, contributing to revenue growth [7][8] - The autonomous driving business is accelerating its globalization, which is anticipated to become a new growth curve for the company [7][8] Financial Forecasts - Total revenue projections for Baidu are as follows: - 2023: 134,598 million - 2024: 133,125 million - 2025: 129,495 million - 2026: 136,140 million - 2027: 142,409 million - Year-on-year growth rates for total revenue are expected to be 8.83% in 2023, -1.09% in 2024, -2.73% in 2025, 5.13% in 2026, and 4.60% in 2027 [1][9] - Net profit attributable to the parent company is forecasted as follows: - 2023: 20,315 million - 2024: 23,760 million - 2025: 21,391 million - 2026: 18,840 million - 2027: 21,682 million - Year-on-year growth rates for net profit are projected at 168.75% in 2023, 16.96% in 2024, -9.97% in 2025, -11.93% in 2026, and 15.08% in 2027 [1][9] - Non-GAAP net profit estimates are as follows: - 2023: 28,747 million - 2024: 27,002 million - 2025: 19,430 million - 2026: 21,714 million - 2027: 24,742 million - Year-on-year growth rates for Non-GAAP net profit are expected to be 39.01% in 2023, -6.07% in 2024, -28.04% in 2025, 11.76% in 2026, and 13.95% in 2027 [1][9] Market Data - The closing price of Baidu's stock is 111.80 HKD, with a market capitalization of approximately 226,525.83 million HKD [5][6] - The price-to-earnings (P/E) ratio is projected to be 13.92 for the current year and 11.91 for the next year [1][9]

Investment Rating - The report upgrades the investment rating of ZTO Express to "Buy" [6] Core Views - In Q3 2025, ZTO Express achieved a revenue of RMB 11.86 billion, a year-on-year increase of 11.1%, with an adjusted net profit of RMB 2.51 billion, reflecting a 5.0% increase year-on-year [1][2] - The growth in express delivery revenue was driven by a 9.8% increase in package volume and a 1.7% increase in average price per package [1] - The company anticipates a total package volume for 2025 to be between 38.2 billion and 38.7 billion, representing a year-on-year growth of 12.3% to 13.8% [2] Summary by Sections Q3 2025 Performance - Adjusted net profit increased by 5.0% year-on-year to RMB 2.51 billion, with a revenue of RMB 11.86 billion [1] - The express delivery business generated RMB 11.02 billion in revenue, up 11.6% year-on-year, supported by a 9.8% increase in package volume [1][2] Operational Data - The company completed 9.57 billion express deliveries in Q3 2025, a 9.8% increase year-on-year, capturing a market share of 19.4% [2] - The number of collection and delivery points exceeded 31,000, with approximately 10,000 owned vehicles [2] Revenue and Cost Analysis - The core revenue per package was RMB 1.22, an increase of RMB 0.02 year-on-year, with cost efficiencies leading to a reduction in sorting and transportation costs [3] - The adjusted net profit per package was RMB 0.26, slightly down from RMB 0.27 in Q3 2024, but improved by RMB 0.05 from Q2 2025 [3] Profit Forecast - ZTO Express is expected to focus on network stability and competitive advantages, with projected net profits for 2025-2027 at RMB 9.62 billion, RMB 11.02 billion, and RMB 12.08 billion respectively [4]

Investment Rating - The investment rating for the company is "Outperform the Market" (maintained) [2][22]. Core Views - The company plans to issue up to 800 million shares of RMB ordinary shares for listing on the Shenzhen Stock Exchange, which represents 11.52% of the total share capital post-issuance. The funds raised will be used for business development and to supplement working capital [3][4]. - The issuance of A-shares is expected to have a limited dilution effect, and the company has sufficient free cash flow to maintain its dividend per share (DPS) [4][18]. - The garbage incineration industry is entering a mature phase, with a slowdown in capacity release. The national capacity for harmless treatment of municipal solid waste has increased to 1.5226 million tons per day, with incineration accounting for 76.08% [4][12]. - The company’s free cash flow has turned positive, reaching HKD 4.416 billion in 2024, indicating a shift from expansion to refined operations, which may lead to a revaluation in the secondary market [18][25]. Summary by Sections Share Issuance Impact - The proposed issuance of A-shares is expected to increase the total share capital from 6.143 billion to 6.943 billion shares, with a potential upper limit of 7.063 billion shares if the overallotment is exercised. The total dividend amount is projected to increase by 11.3% to HKD 15.97 billion, or by 14.9% to HKD 16.24 billion considering the overallotment [10][4]. Industry Analysis - The number of new garbage incineration projects has decreased significantly, with only 20 new projects in 2024, a reduction of 35 from 2023. The total investment in these projects is estimated at approximately HKD 5.26 billion, down about 80% from HKD 28.77 billion in 2023 [4][15]. Financial Performance - The company’s net profit for 2025 is projected to be HKD 3.532 billion, with a growth rate of 4.6% for the following years. The current price-to-earnings ratio (PE) is estimated at 8.7x for 2025, indicating potential for valuation recovery [22][25]. - The company has maintained a consistent dividend policy, with a projected DPS of HKD 0.23 for 2025, reflecting a commitment to returning value to shareholders [25][22]. Valuation Comparison - The current PE ratio of the company’s H-shares is 9.8x, significantly lower than the average issuance PE of over 20x for A-share listed garbage incineration companies, suggesting room for valuation improvement [18][22].

证券研究报告 | 2025年11月24日 携程集团-S（09961.HK） 优于大市 Q3 延续绩优表现，海外份额扩张蓄力中线空间 Q3 旺季收入增速环比平稳，主业利润增速环比改善。2025Q3 公司收入 183.4 亿元/+15.5%，好于彭博预期的 14.6%，环比上半年的 16%增速维持基本稳定； Non-GAAP 归母净利润 191.56 亿元/+221.2%，主要系出售 Makemytrip 带来其 他收益贡献；其中主业相关的经调整 EBITDA 为 63.5 亿元/+11.7%，环比提 速，好于彭博预期的+4.8%，对应利润率为 34.6%/-1.2pct。今年以来海外投 入及占比提升致利润率同比回落，但公司凭借优异执行力带来良好表现。 收入拆分：国内与出境自由行份额继续提升，海外 Trip.com 增势不减。 2025Q3 公司住宿预订收入 80.5 亿元/+18.3%，交通票务收入 63.1 亿元 /+11.6%，旅游度假收入 16.1 亿元/+3.1%，商旅管理收入 7.6 亿元/+15.2%， 其他收入 16.5 亿元/+33.9%。分区域看：1）估算 Q3 国内收入同比增长约 10%， ...

Investment Rating - The investment rating for the company is "Outperform the Market" [6] Core Views - The company has shown a significant recovery in Q3, with revenue exceeding guidance and a notable increase in performance compared to previous quarters. The hotel revenue for Q3 reached approximately 30.6 billion yuan, a year-on-year increase of 17.5% [11] - The company is expected to maintain a stable growth trajectory in Q4, with projected revenue growth of 2-6% and domestic growth of 3-7%. The anticipated growth in franchise revenue is between 17-21% year-on-year [14][15] - The company is focusing on optimizing revenue management and strengthening direct sales channels, which has led to a slight recovery in domestic RevPAR, with a mixed RevPAR of 256 yuan, down only 0.1% year-on-year [12] Summary by Sections Q3 Performance - Q3 revenue was 6.96 billion yuan, up 8.1% year-on-year, surpassing the previous guidance of 2-6%. The net profit attributable to shareholders was 1.47 billion yuan, a 15.4% increase year-on-year [11] - The company’s domestic same-store RevPAR decreased by 4.7% year-on-year, showing a gradual recovery compared to earlier quarters [12] Membership and Revenue Management - The number of members in the company's loyalty program exceeded 300 million, a year-on-year increase of 17.3%. Member bookings increased by 19.7%, accounting for 74% of total room nights [12] - The company has successfully implemented revenue management strategies, resulting in a positive year-on-year growth in average daily rate (ADR) of 0.9% [12] Expansion and Profitability - The company opened 2,038 new stores and closed 483, resulting in a net increase of 1,555 stores. The total number of operating hotels reached 12,600, with a market share estimated at 11% [13] - Franchise revenue and gross operating profit (GOP) increased by 27.4% and 28.6% year-on-year, respectively, while direct store revenue and GOP decreased by 5.5% and 24.7% [13] Future Outlook - The company anticipates a stable or slight increase in domestic RevPAR in Q4, with overall core indicators expected to maintain a healthy development trend [14] - The management expects to exceed the initial target of opening 2,300 new hotels by the end of the year, supported by improved signing and conversion rates [13] Financial Projections - The company has revised its revenue growth projections for 2025-2027, expecting a year-on-year increase of 5.4%, 5.8%, and 6.2%, respectively. Adjusted net profits are projected to be 4.44 billion, 5.17 billion, and 5.78 billion yuan for the same period [15]

Investment Rating - The investment rating for Kuaishou is "Buy" and is maintained [7] Core Insights - Kuaishou's Q3 2025 revenue reached 35.6 billion CNY, representing a year-on-year growth of 14%. The Non-GAAP net profit was 5 billion CNY, up 26% year-on-year. Domestic business operating profit was 5.4 billion CNY, a significant increase of 54% year-on-year, while overseas business incurred an operating loss of 200 million CNY [2][4] Revenue Breakdown - Kuaishou's Q3 2025 online marketing service revenue was 20.1 billion CNY, growing 14% year-on-year, contributing 56.5% to total revenue. The growth was driven by AI-enabled advertising, with ad load and eCPM both improving, leading to a 4-5% increase in domestic advertising revenue. The company also saw a 3% increase in live streaming revenue, totaling 9.6 billion CNY, contributing 26.9% to total revenue. Other services, including e-commerce, generated 5.9 billion CNY, a 41% increase year-on-year, contributing 16.6% to total revenue [8] User Engagement - Kuaishou's content ecosystem continues to thrive, with average daily active users (DAU) reaching 416 million, a 2.1% year-on-year increase, and average monthly active users (MAU) reaching 731 million, up 2.4% year-on-year [8] Profitability Metrics - Kuaishou achieved a gross margin of 54.7% in Q3 2025, with an adjusted net profit margin of 14.0%, reflecting a year-on-year increase of 0.4 percentage points and 1.3 percentage points, respectively. R&D expenses rose by 17.7% to 3.7 billion CNY, primarily due to increased AI investments and employee benefits [8] AI Business Development - The commercialization of Kuaishou's AI, known as Keling, progressed smoothly, generating over 300 million CNY in revenue in Q3 2025, a 20% increase from the previous quarter. The Keling 2.5 Turbo model topped global rankings in video and image generation shortly after its launch [8]

灯塔引领品质房企，精益求精笃行向上 建发国际集团(01908) 证券研究报告 房地产开发 / 公司深度研究报告 / 2025.11.24 投资评级:买入(首次) | 基本数据 | 2025-11-24 | | --- | --- | | 收盘价(元) | 16.95 | | 流通股本(亿股) | 22.40 | | 每股净资产(元) | 13.14 | | 总股本(亿股) | 22.40 | 最近 12 月市场表现 -19% -4% 12% 28% 44% 60% 建发国际集团 恒生指数 房地产开发 分析师 房诚琦 SAC 证书编号：S0160525090002 fangcq@ctsec.com 分析师 何裕佳 SAC 证书编号：S0160525090001 heyj@ctsec.com 分析师 陈思宇 SAC 证书编号：S0160525090008 chensy04@ctsec.com 相关报告 核心观点 盈利预测 | [币种Table_FinchinaSimple] (人民币) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | -- ...

证券研究报告 | 2025年11月24日 网易-S（09999.HK） 优于大市 递延收入增长 25%，经典游戏优异展现长期运营能力 收入同比上升 8%，销售费率环比继续所上升。25Q3，公司实现营收 284 亿 元，同比上升 8%。Non-GAAP 归母净利润 95 亿元，同比增长 27%；Non-GAAP 归母净利率 33.5%，同比提升 5pct。25Q3，公司综合毛利率 64.1%，同 比上升 1.2pct，网易云音乐毛利率同比提升 2.6pct。25Q3，公司总经 营费率为 36%，同比上升 0.2pct，环比上升 4pct。其中销售费率 15.7%， 同比上升 1pct，环比提升 3pct，游戏及相关增值服务市场推广支出增 加。我们预计 25Q4 销售费率环比略下降。 游戏：《梦幻西游》等经典游戏展现长期价值。2025Q3，在线游戏业务收 入为 228 亿元，同比增长 13%。递延收入表现良好，25Q3 网易递延收入 195 亿元，同比增长 25%。25Q3 老游戏表现优异，公司持续布局全球化。 1）多款经典游戏持续受到玩家欢迎，体现了网易游戏强劲的长线运营 能力。自三季度起，《梦幻西游》电脑版的 ...

Investment Rating - The report maintains a "Buy" rating for CSPC Pharmaceutical [8][14] Core Views - CSPC Pharmaceutical reported a revenue of RMB 19.89 billion for the first three quarters of 2025, a decrease of 12.3% year-on-year, with a net profit of RMB 3.51 billion, down 7.1% year-on-year. However, the third quarter showed signs of recovery with a revenue increase of 3.4% year-on-year to RMB 6.62 billion and a net profit increase of 27.2% year-on-year to RMB 964 million, aligning with expectations [5][10] - The company's gross margin decreased by 4.9 percentage points year-on-year to 65.6% in the first three quarters of 2025, with the sales contribution from finished drugs dropping from 82.3% to 77.7% [10][11] - The report highlights a significant decline in oncology product sales, which fell by 56.8% year-on-year to RMB 1.65 billion, representing only 10.7% of total finished drug sales [11] - CSPC has made progress in its innovative pipeline, with 28 key products in pivotal clinical trials and an increase in R&D expenses by 7.9% year-on-year to RMB 4.19 billion, reflecting a commitment to innovation [8][13] Financial Summary - For 2025, the company expects a revenue of RMB 26.785 billion, a decrease of 7.67% year-on-year, and a net profit of RMB 4.559 billion, with an EPS forecast adjusted down to RMB 0.40 [9][14] - The report projects a target price adjustment from HKD 12.7 to HKD 9.7, indicating a potential upside of 31% [14]

Investment Rating - The report maintains a "Buy" rating for CSPC Pharmaceutical [1][14] Core Views - The company reported a 12.3% year-on-year decline in revenue for the first three quarters of 2025, totaling RMB 19.89 billion, while net profit decreased by 7.1% to RMB 3.51 billion. However, in the third quarter, revenue grew by 3.4% year-on-year to RMB 6.62 billion, and net profit increased by 27.2% to RMB 964 million, aligning with expectations [4][10] - The gross margin decreased by 4.9 percentage points year-on-year to 65.6%, with the sales contribution from finished drugs dropping from 82.3% in the first three quarters of 2024 to 77.7% in 2025 [4][10] - The company has a robust pipeline with 28 key products in pivotal clinical trials and a significant increase in R&D expenses, which rose by 7.9% year-on-year to RMB 4.19 billion, representing 21.0% of revenue [7][13] Financial Performance - For the first three quarters of 2025, finished drug sales fell by 17.3% year-on-year to RMB 15.45 billion, but third-quarter sales returned to growth at RMB 5.20 billion, up 1.6% year-on-year [5][11] - The oncology product sales saw a significant decline of 56.8% year-on-year to RMB 1.65 billion, now representing 10.7% of total finished drug sales [5][11] - The API segment experienced a 22.3% year-on-year increase in vitamin C revenue to RMB 1.79 billion, while antibiotic API revenue slightly declined by 3.7% due to price drops [5][11] Pipeline Development - The company is advancing multiple trials for SYS6010 (EGFR ADC), which has received Fast Track Designation from the FDA and Breakthrough Therapy Designation from the NMPA, with data readouts expected in 2026 [6][12] - The innovative pipeline includes 28 products in phase II/III trials, nine in phase II, and approximately 40 in phase I, covering both oncology and non-oncology areas [7][13] Earnings Forecast - The earnings per share (EPS) forecast for 2025 has been adjusted down from RMB 0.46 to RMB 0.40, with target prices revised from HK$12.7 to HK$9.7, indicating a potential upside of 31% [14]